The METAP2 inhibitor SDX-7320 reduced obesity-accelerated tumor growth more effectively than tirzepatide while causing less weight loss, suggesting direct anti-tumor effects beyond metabolic improvements.
Greater tumor inhibitionSDX-7320 outperformed tirzepatide for tumor growth inhibition despite causing less weight loss in obese mice
What the researchers found
SDX-7320 significantly attenuated obesity-accelerated tumor growth in three syngeneic mouse models and outperformed tirzepatide for tumor inhibition despite causing less weight loss, indicating direct anti-tumor mechanisms.
Why it matters
Obesity-associated cancers represent a growing clinical challenge. A drug that addresses both obesity and directly fights tumors could fill an unmet need, and this study provides the first evidence that METAP2 inhibition can do both.
How the study worked
Preclinical study using diet-induced obese mice and rats with syngeneic tumor models (B16F10, EO771, MC38), pharmacokinetic-pharmacodynamic analysis, RNA-Seq tumor profiling, and plasma metabolomics.
What this study cannot tell us
Entirely preclinical (mouse/rat models) — results may not translate to humans. Syngeneic tumor models don't perfectly replicate human cancer biology. No human safety or efficacy data presented. Long-term effects unknown.
How to read the evidence
Preclinical study with multiple animal models, mechanistic profiling via RNA-Seq and metabolomics, and head-to-head comparison with an established drug. Strong preclinical evidence but no human data.
When this study was published
Published in 2025, representing early-stage development of a novel peptidase inhibitor for obesity-associated cancer.
The bigger picture
This research sits at the intersection of peptide biology, obesity pharmacology, and oncology. By comparing a peptidase inhibitor to a peptide-based drug (tirzepatide) and showing different mechanisms of action, it highlights how targeting peptide processing enzymes can have therapeutic effects distinct from peptide receptor agonism.
Questions still open
- Will SDX-7320 show similar anti-tumor effects in human clinical trials for obese cancer patients?
- Could combining SDX-7320 with tirzepatide provide synergistic benefits given their non-overlapping mechanisms?
- What are the safety implications of long-term METAP2 inhibition in humans?
Common questions
What is METAP2 and why does inhibiting it fight cancer?
How does SDX-7320 compare to GLP-1 drugs like tirzepatide?
Read the original research
Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth.
Frontiers in oncology, 16, 1751681
Citation
Cornelius, Peter; Mayes, Benjamin A; Dannenberg, Andrew J; Dufour, Pierre J; Little, Sara; Guzior, Douglas V; Petersen, John S; Shanahan, James M; Carver, Bradley J. (2026). Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth.. Frontiers in oncology, 16, 1751681. https://doi.org/10.3389/fonc.2026.1751681